OSRHW 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• In June 2026, the Company announced a shareholder loyalty program (the “Loyalty Program”) under which the Company intends to distribute one non-transferable contingent value right (“CVR”) for each share of the Company’s common stock held of record as of the record date, which is August 14, 2026. To …

• Measurement date Closing-price threshold Shares delivered per CVR Cumulative position

• The CVRs are non-transferable and have no standalone value, and the distribution of CVRs and any delivery of shares remain subject to an effective registration statement or an available exemption, applicable Nasdaq listing requirements, and other conditions. A more detailed description of the Loyalt…

• On July 31, 2026, the Company announced that Nasdaq had informed the Company, in a verbal communication, that the Loyalty Program would not result in any mechanical adjustment to the price of the Company’s common stock, either upon the distribution of the CVRs or upon the delivery of additional shar…

• Comparison of the Three and Six Months Ended June 30, 2025 and 2026

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• On March 27, 2026, the Company, together with its wholly owned subsidiary Vaximm AG, entered into a binding term sheet with BCM Europe AG relating to a revised global exclusive license arrangement for VXM01. The term sheet supersedes and replaces the prior agreement dated January 13, 2025.

• Additional information is set forth in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on April 2, 2026, which is incorporated herein by reference.

• Subsequently, on April 29, 2026, the Company and Vaximm entered into a definitive Global Exclusive License Agreement with BCME, pursuant to which BCME was granted an exclusive, worldwide, sublicensable license to develop and commercialize VXM01. The agreement provides for potential milestone payment…

• In connection with the foregoing transaction, the parties also entered into a Pledge Agreement pursuant to which BCME and its affiliates pledged their OSR Holdings, Inc. common stock to the Company as collateral security for BCME’s milestone payment obligations under the Global Exclusive License Agr…

• Additional information regarding the foregoing is set forth in the Company’s Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission on April 2, 2026 and April 29, 2026, respectively, which are incorporated herein by reference.

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• On April 7, 2026, the Company entered into Amendment No. 2 to the Common Stock Purchase Agreement with White Lion, as disclosed in the Company’s Current Report on Form 8-K filed on April 9, 2026.

• The amendment enhances the Company’s flexibility under its equity line of credit by introducing intraday and fixed purchase notice mechanisms, each subject to specified conditions and based on discounted volume-weighted average price (“VWAP”) formulas. The amendment also provides for related settlem…

• 10.6 Asset Purchase Agreement, dated May 27, 2026, between OSR Health, Inc.(f/k/a OSR Holdings, Inc) and Vaximm AG (previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 2, 2026 and incorporated herein by reference)

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• As further amended on April 7, 2026, the Common Stock Purchase Agreement was modified to revise certain defined terms, including “Purchase Notice” and “Purchase Notice Limit,” and to introduce additional purchase notice mechanisms, including intraday purchase notices and fixed purchase notices, prov…